A quote from the article...
We have developed a peptide-based therapeutic vaccine based on the dominant problem T-cell epitopes of gluten. The "vaccine" has the potential to treat at about 80% of people with the disease and having the appropriate genetic background. In common with traditional desensitization therapy for allergy, peptide-based therapeutic vaccines administered in many small doses over a course of injections could induce immune tolerance not only to the selected gluten fragments but also suppress the toxicity of other toxic gluten components," explained Dr Anderson. Dr Anderson is joint founder and CEO of Nexpep Pty Ltd, the company developing the coeliac vaccine in Australia. Dr Anderson said, "Nexpep is currently raising capital for a clinical trial program for a peptide-based therapeutic vaccine and intends to commence a Phase 1 clinical trial in the first half of 2009.Interesting...
1 comments:
http://www.celiac.com/articles/21712/1/Celiac-Disease-Vaccine-Trials-Slated-for-2009/Page1.html
Post a Comment